Objective: In the manuscript titled “Liquid subcutaneous Levodopa-Carbidopa ND0612 effects on motor symptoms in individuals with Parkinson’s Disease: A systematic review and meta-analysis”, the objective was to conduct a systematic review with meta-analysis to investigate the effects ND0612 24-hour dosing regimen has on motor symptoms in individuals with Parkinson’s Disease (PD). Introduction: ND0612 is a novel minimally invasive continuous subcutaneous delivery system of liquid Levodopa-Carbidopa being investigated for the treatment of PD in individuals experiencing motor symptoms. Methods: A systematic literature search was conducted in PubMed, Cochrane, and EBSCO databases to identify randomized controlled trials investigating the effects of ND0612 on motor symptoms in individuals with PD. Outcomes included the Unified Parkinson’s Disease Rating Scale (UPDRS) Part II and Part III scores. Methodological quality was assessed using the Cochrane Grading of Recommendations Assessment, Development, and Evaluation approach. Meta-analysis was performed using a random effects model with the DerSimonian and Laird method to estimate the effects of the ND0612 24-hour dosing regimen on UPDRS Part II and Part III scores. Results: Three studies were included in our review. There were statistically significant reductions in UPDRS Part II scores (mean difference (MD) −3.299; 95% confidence interval (CI) −3.438, −3.159) and in UPDRS Part III scores (MD −12.695; 95% CI −24.428, −0.962) in the ND0612 24-hour dosing regimen. Results were based on very low certainty of evidence. Conclusion: Based on very low certainty evidence, the ND0612 24-hour dosing regimen is effective at improving motor symptoms in individuals with PD. Our findings suggest that ND0612 is more effective at improving UPDRS Part II and Part III scores in individuals with PD than other pharmacological and non-pharmacological treatments, warranting further study.
References
[1]
Emamzadeh, F.N. and Surguchov, A. (2018) Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors. Frontiers in Neuroscience, 12, Article No. 612. https://doi.org/10.3389/fnins.2018.00612
[2]
Alexander, G.E. (2004) Biology of Parkinson’s Disease: Pathogenesis and Pathophysiology of a Multisystem Neurodegenerative Disorder. Dialogues in Clinical Neuroscience, 6, 259-280. https://doi.org/10.31887/DCNS.2004.6.3/galexander https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181806/
[3]
American Association of Neurological Surgeons (2023) Parkinson’s Disease—Symptoms, Diagnosis and Treatment. https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Parkinsons-Disease#:~:text=Without enough dopamine, this balance
[4]
Lanciego, J.L., Luquin, N. and Obeso, J.A. (2012) Functional Neuroanatomy of the Basal Ganglia. Cold Spring Harbor Perspectives in Medicine, 2, a009621. https://doi.org/10.1101/cshperspect.a009621
[5]
Kalia, L.V. and Lang, A.E. (2015) Parkinson’s Disease. The Lancet, 386, 896-912. https://doi.org/10.1016/S0140-6736(14)61393-3
[6]
Vieira de Moraes Filho, A., Chaves, S.N., Martins, W.R., et al. (2020) Progressive Resistance Training Improves Bradykinesia, Motor Symptoms and Functional Performance in Patients with Parkinson’s Disease. Clinical Interventions in Aging, 15, 87-95. https://doi.org/10.2147/CIA.S231359
[7]
Giladi, N., Gurevich, T., Djaldetti, R., et al. (2021) ND0612 (Levodopa/Carbidopa for Subcutaneous Infusion) in Patients with Parkinson’s Disease and Motor Response Fluctuations: A Randomized, Placebo-Controlled Phase 2 Study. Parkinsonism & Related Disorders, 91, 139-145. https://doi.org/10.1016/j.parkreldis.2021.09.024
[8]
Tambasco, N., Romoli, M. and Calabresi, P. (2018) Levodopa in Parkinson’s Disease: Current Status and Future Developments. Current Neuropharmacology, 16, 1239-1252. https://doi.org/10.2174/1570159X15666170510143821
[9]
Olanow, C.W., Agid, Y., Mizuno, Y., et al. (2004) Levodopa in the Treatment of Parkinson’s Disease: Current Controversies. Movement Disorders, 19, 997-1005. https://doi.org/10.1002/mds.20243
[10]
Poewe, W., Antonini, A., Zijlmans, J.C., Burkhard, P.R. and Vingerhoets, F. (2010) Levodopa in the Treatment of Parkinson’s Disease: An Old Drug Still Going Strong. Clinical Interventions in Aging, 5, 229-238. https://doi.org/10.2147/CIA.S6456
[11]
Freitas, M.E., Hess, C.W. and Fox, S.H. (2017) Motor Complications of Dopaminergic Medications in Parkinson’s Disease. Seminars in Neurology, 37, 147-157. https://doi.org/10.1055/s-0037-1602423
[12]
Parkinson Study Group (2000) Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease. JAMA, 284, 1931-1938. https://doi.org/10.1001/jama.284.15.1931
[13]
LeWitt, P.A., Stocchi, F., Arkadir, D., et al. (2022) The Pharmacokinetics of Continuous Subcutaneous Levodopa/Carbidopa Infusion: Findings from the ND0612 Clinical Development Program. Frontiers in Neurology, 13, Article ID: 1036068. https://doi.org/10.3389/fneur.2022.1036068
[14]
Maratos, E.C., Jackson, M.J., Pearce, R.K.B., Cannizzaro, C. and Jenner, P. (2003) Both Short-and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus). Experimental Neurology, 179, 90-102. https://doi.org/10.1006/exnr.2002.8055
[15]
Gagnon, C., Bédard, P.J. and Di Paolo, T. (1990) Effect of Chronic Treatment of MPTP Monkeys with Dopamine D-1 and/or D-2 Receptor Agonists. European Journal of Pharmacology, 178, 115-120. https://doi.org/10.1016/0014-2999(90)94802-5
[16]
Gomez-Mancilla, B. and Bédard, P.J. (1992) Effect of Chronic Treatment with ( )-PHNO, a D2 Agonist in MPTP-Treated Monkeys. Experimental Neurology, 112, 185-188. https://doi.org/10.1016/0014-4886(92)90125-A
[17]
Bédard, P.J., Paolo, T.D., Falardeau, P. and Boucher, R. (1986) Chronic Treatment with L-DOPA, but Not Bromocriptine Induces Dyskinesia in MPTP-Parkinsonian Monkeys. Correlation with [3H]spiperone Binding. Brain Research, 379, 294-299. https://doi.org/10.1016/0006-8993(86)90783-3
[18]
Maratos, E.C., Jackson, M.J., Pearce, R.K.B. and Jenner, P. (2001) Antiparkinsonian Activity and Dyskinesia Risk of Ropinirole and L-DOPA Combination Therapy in Drug Naive MPTP-Lesioned Common Marmosets (Callithrix jacchus). Movement Disorders, 16, 631-641. https://doi.org/10.1002/mds.1149
[19]
Blanchet, P.J., Calon, F., Martel, J.C., et al. (1995) Continuous Administration Decreases and Pulsatile Administration Increases Behavioral Sensitivity to a Novel Dopamine D2 Agonist (U-91356A) in MPTP-Exposed Monkeys. The Journal of Pharmacology and Experimental Therapeutics, 272, 854-859. https://pubmed.ncbi.nlm.nih.gov/7853204/
[20]
Morissette, M., Goulet, M., Soghomonian, J.J., et al. (1997) Preproenkephalin mRNA Expression in the Caudate-Putamen of MPTP Monkeys after Chronic Treatment with the D2 Agonist U91356A in Continuous or Intermittent Mode of Administration: Comparison with L-DOPA Therapy. Brain Research Molecular Brain Research, 49, 55-62. https://doi.org/10.1016/S0169-328X(97)00123-X
[21]
Page, M.J., McKenzie, J.E., Bossuyt, P.M., et al. (2021) The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. British Medical Journal, 372, n71.
[22]
Scanlon, B.K., Katzen, H.L., Levin, B.E., Singer, C. and Papapetropoulos, S. (2008) A Formula for the Conversion of UPDRS-III Scores to Hoehn and Yahr Stage. Parkinsonism & Related Disorders, 14, 379-380. https://doi.org/10.1016/j.parkreldis.2007.09.010
[23]
Shulman, L.M., Gruber-Baldini, A.L., Anderson, K.E., Fishman, P.S., Reich, S.G. and Weiner, W.J. (2010) The Clinically Important Difference on the Unified Parkinson’s Disease Rating Scale. Archives of Neurology, 67, 64-70. https://doi.org/10.1001/archneurol.2009.295
[24]
Clarke, C.E., Smitaa, P., Ives, N., et al. (2016) UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria. https://www.ncbi.nlm.nih.gov/books/NBK379754/
[25]
Sterne, J.A.C., Savović, J., Page, M.J., et al. (2019) RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials. BMJ, 366, l4898. https://doi.org/10.1136/bmj.l4898
[26]
Olanow, C.W., Espay, A.J., Stocchi, F., et al. (2021) Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study. Journal of Parkinson’s Disease, 11, 177-186. https://doi.org/10.3233/JPD-202285
[27]
Poewe, W., Stocchi, F., Arkadir, D., et al. (2021) Subcutaneous Levodopa Infusion for Parkinson’s Disease: 1-Year Data from the Open-Label beyond Study. Movement Disorders, 36, 2687-2692. https://doi.org/10.1002/mds.28758
[28]
(2019) Cochrane. 9.5.2 Identifying and Measuring Heterogeneity. https://handbook-5-1.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm
[29]
(2019) Cochrane. 10.4.3.1 Recommendations on Testing for Funnel Plot Asymmetry. https://handbook-5-1.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm
[30]
Zeng, L., Brignardello-Petersen, R., Hultcrantz, M., et al. (2021) GRADE Guidelines 32: GRADE Offers Guidance on Choosing Targets of GRADE Certainty of Evidence Ratings. Journal of Clinical Epidemiology, 137, 163-175. https://doi.org/10.1016/j.jclinepi.2021.03.026
[31]
Deal, L.S., Flood, E., Myers, D.E., Devine, J. and Gray, D.L. (2019) The Parkinson’s Disease Activities of Daily Living, Interference, and Dependence Instrument. Movement Disorders Clinical Practice, 6, 678-686. https://doi.org/10.1002/mdc3.12833
[32]
Parkinson Study Group (2002) A Controlled Trial of Rasagiline in Early Parkinson Disease. Archives of Neurology, 59, 1937-1943. https://doi.org/10.1001/archneur.59.12.1937
[33]
Parkinson Study Group (2004) A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease. Archives of Neurology, 61, 561-566. https://doi.org/10.1001/archneur.61.4.561
[34]
Nayak, L. and Henchcliffe, C. (2008) Rasagiline in Treatment of Parkinson’s Disease. Neuropsychiatric Disease and Treatment, 4, 23-32. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515917/ https://doi.org/10.2147/NDT.S464
[35]
Stern, M.B., Marek, K.L., Friedman, J., et al. (2004) Double-Blind, Randomized, Controlled Trial of Rasagiline as Monotherapy in Early Parkinson’s Disease Patients. Movement Disorders, 19, 916-923. https://doi.org/10.1002/mds.20145
[36]
Yang, C.L., Huang, J.P., Wang, T.T., et al. (2022) Effects and Parameters of Community-Based Exercise on Motor Symptoms in Parkinson’s Disease: A Meta-Analysis. BMC Neurology, 22, Article No. 505. https://doi.org/10.1186/s12883-022-03027-z
